doi:10.3969/j.issn.1673-8640.2018.09.022

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 9

[1]	NADERI N,YANG D T.Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia[J]. Arch Pathol Lab Med,2013,137(4):580-585.
[2]	中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组,中国抗淋巴瘤联盟. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(9):729-734.
[3]	VARETTONI M, ARCAINI L, ZIBELLINI S, et al.Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms[J]. Blood, 2013, 121(13):2522-2528.
[4]	TREON S P, XU L, YANG G, et al.MYD88 L265P somatic mutation in Waldenström's macroglobulinemia[J]. N Engl J Med, 2012, 367(9):826-833.
[5]	TREON S P, HUNTER Z R, CASTILLO J J, et al.Waldenström macrogloblinemia[J]. Hematol Oncol Clin North Am,2014,28(5):945-970.
[6]	陈海敏, 侯健. MyD88 L265P突变与B细胞肿瘤[J]. 中国实验血液学杂志, 2014, 22(1):241-244.
[7]	SCHMIDT J, FEDERMANN B, SCHINDLER N, et al.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity[J]. Br J Haematol,2015,169(6):795-803.
[8]	XU L, HUNTER Z R, YANG G, et al.Detection of MYD88 L265P in peripheral blood of patients with Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance[J]. Leukemia, 2014, 28(8):1698-1704.
[9]	余思思, 黄建鸣, 张智慧. 弥漫大B细胞淋巴瘤MYD88 L265P突变研究进展[J]. 肿瘤预防与治疗, 2016, 29(2):119-122.

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 9

Related Articles 15

Recommended Articles

Metrics